dm+d

Unassigned

New Medicines

COVID-19 treatment in non-hospitalised adults with mild to moderate disease

Information

New molecular entity
MSD
Merck

Development and Regulatory status

Phase III Clinical Trials
Phase III Clinical Trials
Phase III Clinical Trials

Category

Ribonucleoside analog β-D-N4-hydroxycytidine broad spectrum antiviral
Coronavirus disease 2019 (COVID-19) is a new pandemic disease caused by the severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2). Most cases are mild respiratory illnesses. However, around 20% require hospitalisation, mostly due to pneumonia, and can progress quickly to severe acute lung injury and acute respiratory distress syndrome (ARDS), which is associated with high mortality. A viral-induced cytokine storm is thought to be involved with the pulmonary complications [1].
COVID-19 treatment in non-hospitalised adults with mild to moderate disease
Oral